

Table SI. Demographic and clinical characteristics of the patients.

Characteristic	Value
Age, years	46 (21-72)
Gender	
Male	45 (71.42)
Female	18 (28.57)
Pathology	
DLBCL	47 (74.60)
Primary central DLBCL	4 (6.34)
Primary mediastinal DLBCL	2 (3.17)
Follicular cell lymphoma	5 (7.93)
B-cell lymphoma leukemia	4 (6.34)
Mantle cell lymphoma	1 (1.58)
Number of prior chemotherapies, times	8 (3-26)
Prior allogeneic HSCT	4 (6.34)
Targets of CAR-T cells	
CD19	11 (17.46)
CD20	9 (14.28)
CD19-CD20	23 (36.50)
CD19-CD22	19 (30.15)
CD19-NK	1 (1.58)
Prior bridging therapy	9 (14.28)
CRS	
None	19 (30.15)
Grade 1-2	40 (63.49)
Grade $\geq 3$	4 (6.34)
NT	
None	53 (84.12)
Grade 1-2	7 (11.11)
Grade $\geq 3$	3 (4.76)
Response	
CR	11 (18.3)
PR	28 (46.7)
SD	12 (20)
PD	9 (15)

Values are expressed as the median (range) or n (%). DLBCL, diffuse large B-cell lymphoma; CAR-T, chimeric antigen receptor T-cell; CRS, cytokine release syndrome; NT, neurological toxicity; NK, natural killer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Table SII. Analysis of risk factors for neutropenia above grade 3.

Characteristic	Neutropenia group	No neutropenia group	Univariate analysis P
Gender			0.195
Male	32 (66.66)	13 (86.67)	
Female	16 (33.34)	2 (13.33)	
Age, years	47 (21-72)	45 (24-70)	0.600
ECOG score	2 (0-3)	1 (0-3)	0.026
Number of prior chemotherapies, times	8 (3-24)	10 (6-26)	0.147
Prior autologous HSCT			1.000
Yes	3 (6.25)	1 (6.67)	
No	45 (93.75)	14 (93.33)	
Bone marrow involvement			0.667
Yes	7 (14.5)	1 (6)	
No	41 (85.5)	14 (94)	
Targets of CAR-T cells			0.503
CD19	8 (16.67)	3 (20)	
CD20	7 (14.58)	2 (13.33)	
CD19-CD20	17 (35.41)	6 (40)	
CD19-CD22	16 (33.33)	3 (20)	
CD19-NK	0 (0)	1 (6.67)	
CRS			0.380
None	16 (33.33)	3 (20)	
Grade 1-2	28 (58.33)	12 (80)	
Grade $\geq$ 3	4 (8.33)	0 (0)	
NT			1.000
None	40 (83.33)	13 (86.67)	
Grade 1-2	5 (10.41)	2 (13.33)	
Grade $\geq$ 3	3 (6.25)	0 (0)	
Baseline ANC, $\times 10^9/l$	2.86 (0.61-11.35)	4.31 (1.55-7.01)	0.005
Baseline hemoglobin, g/l	106 (51-149)	127 (103-165)	<0.001
Baseline platelet count, $\times 10^9/l$	157 (23-359)	212 (127-447)	0.158
Baseline CRP, mg/l	18.25 (0.40-200)	5.8 (0.4-114.70)	0.113
Baseline ferritin, ng/ml	613.60 (20-25822)	324.1 (33.10-830)	0.014
Baseline IL-6, pg/l	12.31 (1.50-882)	4.24 (1.50-25)	0.004

Values are expressed as n (%) or the median (range). CRP, C-reactive protein; CAR-T, chimeric antigen receptor T-cell; ANC, absolute neutrophil count; CRS, cytokine release syndrome; NT, neurological toxicity; NK, natural killer; HSCT, hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group.

Table SIII. Analysis of risk factors for anemia above grade 3.

Characteristic	Anemia group	No anemia group	Univariate analysis P
Gender			0.522
Male	13 (81.3)	32 (68.1)	
Female	3 (18.8)	15 (13.9)	
Age, years	46 (23-68)	46 (21-72)	0.680
ECOG score	2 (1-3)	1 (0-3)	0.032
Number of prior chemotherapies, times	9 (3-25)	8 (3-26)	0.281
Prior autologous HSCT			1.000
Yes	1 (6.3)	3 (6.4)	
No	15 (93.8)	44 (93.6)	
Bone marrow involvement			0.407
Yes	3 (18.8)	5 (10.6)	
No	13 (81.3)	42 (89.4)	
Targets of CAR-T cells			0.723
CD19	3 (18.8)	8 (17)	
CD20	1 (6.3)	8 (17)	
CD19-CD20	8 (50)	15 (31.9)	
CD19-CD22	4 (25)	15 (31.9)	
CD19-NK	0 (0)	1 (2.1)	
CRS			0.132
None	2 (12.5)	17 (36.2)	
Grade 1-2	12 (75)	28 (59.6)	
Grade $\geq$ 3	2 (12.5)	2 (4.3)	
NT			1.000
None	13 (81.3)	40 (85.1)	
Grade 1-2	2 (12.5)	5 (10.6)	
Grade $\geq$ 3	1 (6.3)	2 (4.3)	
Baseline ANC, $\times 10^9/l$	2.45 (0.71-11.35)	3.25 (0.61-7.01)	0.522
Baseline hemoglobin, g/l	80 (51-107)	119 (85-165)	<0.001
Baseline platelet count, $\times 10^9/l$	91 (23-301)	191 (54-447)	0.001
Baseline CRP, mg/l	56.05 (5-200)	5.8 (0.4-200)	<0.001
Baseline ferritin, ng/ml	1493 (128.5-25822)	426 (20-1299)	<0.001
Baseline IL-6, pg/l	25.86 (5.05-882)	5.88 (1.50-101.90)	<0.001

Values are expressed as n (%) or the median (range). CRP, C-reactive protein; CAR-T, chimeric antigen receptor T-cell; ANC, absolute neutrophil count; CRS, cytokine release syndrome; NT, neurological toxicity; NK, natural killer; HSCT, hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group.

Table SIV. Analysis of risk factors for thrombocytopenia above grade 3.

Characteristic	Thrombocytopenia group	No thrombocytopenia group	Univariate analysis P
Gender			0.522
Male	12 (80)	33 (68.8)	
Female	3 (20)	15 (31.3)	
Age, years	45 (24-72)	46 (21-70)	0.910
ECOG score	2 (1-3)	1 (0-3)	0.018
Number of prior chemotherapies, times	8 (3-24)	8 (3-26)	0.981
Prior autologous HSCT			0.238
Yes	2 (13.3)	2 (4.2)	
No	13 (86.7)	46 (95.8)	
Bone marrow involvement			1.000
Yes	2 (13.3)	6 (12.5)	
No	13 (86.7)	42 (87.5)	
Targets of CAR-T cells			0.818
CD19	3 (20)	8 (16.7)	
CD20	1 (6.7)	8 (16.7)	
CD19-CD20	7 (46.7)	16 (33.3)	
CD19-CD22	4 (26.7)	15 (31.3)	
CD19-NK	0 (0)	1 (2.1)	
CRS			0.047
None	1 (6.7)	18 (37.5)	
Grade 1-2	13 (86.7)	27 (56.3)	
Grade $\geq$ 3	1 (6.7)	3 (6.3)	
NT			0.573
None	12 (80)	41 (85.4)	
Grade 1-2	2 (13.3)	5 (10.4)	
Grade $\geq$ 3	1 (6.7)	2 (4.2)	
Baseline ANC, $\times 10^9/l$	2.90 (0.71-11.35)	3.27 (0.61-7.01)	0.345
Baseline hemoglobin, g/l	81 (51-130)	117 (77-165)	<0.001
Baseline platelet count, $\times 10^9/l$	72 (23-262)	204 (76-447)	<0.001
Baseline CRP, mg/l	62.1 (5-200)	5.9 (0.4-200)	0.001
Baseline ferritin, ng/ml	1299 (314.2-25822)	425.5 (20-3323)	<0.001
Baseline IL-6, pg/l	26 (5.05-882)	5.97 (1.50-147.4)	<0.001

Values are expressed as n (%) or the median (range). CRP, C-reactive protein; CAR-T, chimeric antigen receptor T-cell; ANC, absolute neutrophil count; CRS, cytokine release syndrome; NT, neurological toxicity; NK, natural killer; HSCT, hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group.

Table SV. Analysis of the relationship between CRS and thrombocytopenia above grade 3.

CRS	Thrombocytopenia group	No thrombocytopenia group	P-value (vs. none)
None	1 (5.3)	18 (94.7)	
Grade 1-2	13 (32.5)	27 (67.5)	0.024
Grade 3-4	1 (2.5)	3 (7.5)	0.324

CRS, cytokine release syndrome.